Clinical Pharmacokinetics of Meloxicam

@article{Davies1999ClinicalPO,
  title={Clinical Pharmacokinetics of Meloxicam},
  author={Neal M. Davies and Neil M. Skjodt},
  journal={Clinical Pharmacokinetics},
  year={1999},
  volume={36},
  pages={115-126}
}
Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclooxygenase-2.Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration. Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces. Meloxicam and its… 
Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety
TLDR
The pharmacokinetics of meloxicam enables once daily application, which increases compliance compared with some shorter acting NSAIDs; however, long-term clinical data clearly demonstrating safety and efficacy advantages are lacking.
Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug
TLDR
Meloxicam is at least as effective as nonselective NSAIDs in the treatment of rheumatic disease or postoperative pain, but has a more favourable gastrointestinal tolerability profile and may also have a cardioprotective role.
Pharmacokinetics of meloxicam in healthy donkeys.
TLDR
A fast elimination with short half life and higher clearance are suggestive that current dosage regimens of meloxicam may not be clinically effective in donkeys and further research is recommended.
A Validated Hplc Method for the Determination of Meloxicam in pharmaceutical preparations
Meloxicam (MEL) (4-hydroxy-2-methyl-N-(5-methyl-2-thiazoly)-2H1,2-benzo-thiazine -3-carboxamide-1,1dioxide) (C14H13N3O4S2) (Figure 1) is a non-steroidal anti-inflammatory drug (NSAID) with a
Pharmacokinetics of meloxicam in plasma and urine of horses.
TLDR
Results of this study support once-daily administration of meloxicam regardless of the feeding status of a horse and suggest a period of at least 3 days before urine concentrations ofmeloxicam reach concentrations that could be used in drug control programs.
PHARMACOKINETIC DRUG-DRUG INTERACTIONS EVALUATION OF MELOXICAM WITH SELECTED CO-PRESCRIBED DRUGS
TLDR
Meloxicam in healthy human volunteers from Pakistan was evaluated and then potential pharmacokinetic drug-drug interaction of meloxicam with selected co-prescribed drugs i.e. omeprazole and fluconazole was investigated, showing an increase in Cmax ofmeloxicam.
A comparison between the effects of meloxicam and other nsaids on the production of oxyradicals by human polymorphonuclear leucocytes
TLDR
Meloxicam is a potent inhibitor of oxyradical production at drug concentrations comparable with those encountered during therapy and, while relatively complex, involves effects which are stimulus dependent and myeloperoxidase sensitive.
Pharmacokinetics of meloxicam in Korean Healthy Volunteers
TLDR
The pharmacokinetic characteristics of meloxicam in Korean are investigated to compare it with those previously published in other races and to pay attention to refer the previous data from other races for a new study design in Korean.
Voriconazole Increases while Itraconazole Decreases Plasma Meloxicam Concentrations
TLDR
Voriconazole increases plasma concentrations of meloxicam, whereas itraconazole, unexpectedly, decreases plasmameloxicam concentrations, possibly by impairing its absorption.
Meloxicam
TLDR
In clinical trials of meloxicam in osteoarthritis, it was found to be as effective as piroxicam, diclofenac and naproxen with less clinical gastrointestinal symptoms and less perforations, obstructions and bleeds by meta-analysis.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
A review of the clinical pharmacokinetics of meloxicam.
TLDR
Neither hepatic insufficiency nor moderate renal dysfunction have any relevant effects on the pharmacokinetics of meloxicam and dosage adjustments in the elderly are not required.
Clinical pharmacokinetics of meloxicam.
TLDR
The results indicate that meloxicam is suitable for once-daily administration and that a switch from one formulation to another is easily possible if necessary or convenient for the patient.
Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects.
TLDR
Meloxicam was extensively metabolized, with only traces of the drug appearing unchanged in urine and feces, and > 95% of the dose excreted could be accounted for by the metabolites identified or the parent compound itself.
Pharmacokinetics and tolerability of meloxicam after i.m. administration.
TLDR
The excellent tolerability of i.m. meloxicam together with its rapid and complete absorption may provide an alternative to oral administration of this drug.
Biological activity of the main metabolites of meloxicam.
TLDR
It can be concluded that the metabolites of Meloxicam do not change renal blood flow and therefore have no capability for nephrotoxicity, in accordance with the observations in the rat kidney during subacute and chronic toxicity studies, where no neph rotoxic effects could be detected after therapeutic doses.
Interaction of Meloxicam with Cimetidine, Maalox, or Aspirin
TLDR
Meloxicam was well tolerated, and concomitant treatment with cimetidine or Maalox had little or no effect on the plasma concentration—time curves, maximum plasma concentration (Cmax), or the area under the plasma concentrations—time curve (AUC0‐∞) of meloxicam.
Clinical Pharmacokinetics of Diclofenac
TLDR
Diclofenac is eliminated following biotransformation to glucoroconjugated and sulphate metabolites which are excreted in urine, very little drug is eliminated unchanged, and the excretion of conjugates may be related to renal function.
Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer
TLDR
It is demonstrated that the in vitro and in vivo pharmacological profile of meloxicam is structurally dependent and that minor structural changes can lead to significant differences in the selectivity for COx-1 and COX-2 in vitroand to different profiles in vivo suggesting different therapeutic potential.
The effect of meloxicam on the pharmacokinetics of beta-acetyl-digoxin.
TLDR
It is concluded that co-treatment with meloxicam has no effect on the pharmacokinetics of oral digoxin.
Meloxicam pharmacokinetics in renal impairment.
TLDR
There is no necessity for a dosage adjustment when administering meloxicam to patients with mild to moderate renal impairment, andMeloxicam was well tolerated with few adverse events occurring and no difference in incidence observable between groups.
...
1
2
3
...